Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

i

Akisik E, Dalay N. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and

breast cancer risk. Exp Mol Pathol 2004; 76: 260-263

Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer

and lymphoma. Nat Med 1997; 3:917–921.

Ameyaw MM, Thornton N, McLeod HL. Re: Population based, case-control study of HER2

genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92:1947.

Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH.

Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118: 499–509.

Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer

biomarkers. J Proteome Res 2005; 4:1123–1133.

Antoniou A, Pharoah PD, Narod S. Average risks of breast and ovarian cancer associated with

BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined

analysis of 22 studies. Am J Hum Genet 2003; 72:1117-1130.

Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes

involved in epithelial ovarian cancer. J Int Oncol 2000; 16: 567– 76.

Bain C, Purdie D, Green A, Siskind V, Harvey P, Ambrosini G. Exercise may protect against

ovarian cancer. Am J Epidemiol 1996; 143: S72.

Bao R, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an

ovarian-specific promoter. Gynecol Oncol 2002; 84: 228–234.

Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene

by a point mutation altering the transmembrane domain of p185. Cell 1986; 45:649–657.

Barrand MA, Heppellparton AC, Wright KA, Rabbitts PH, Twentyman PR. A 190-kilodalton

protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its

relationship to the MRP gene. J Natl Cancer Inst 1994; 86: 110–117.

Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond

trastuzumab. BioDrugs. 2007; 21:69–77.

Bauer HM, Greer CE, Manos MM. Determination of genital HPV infection using consensus

PCR: In Diagnostic Molecular Pathology: a Practical Approach, C.S. Herrington & J. O. McGee

1992; 131–152.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

ii

Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR. Determinants of

genital papillomavirus infection in low-risk women in Portland, Oregon. Sex Trans Dis 1993;

20:274–278.

Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer

2005; 12:S17–27.

Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrere F, Turhan A, Brousse N, Hermine O,

Ribrag V. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin

Cancer Res 2004; 10: 3029–3034

Bercovich JA, Centeno CR, Aguilar SG, Grinstein S, Kahn T. Presence and integration of

human papillomavirus type 6 in a tonsillar carcinoma. J Gen Virol 1999; 72: 2569-2572.

Bergman A, Einbeigi Z, Olofsson U, Taib Z, Wallgren A, Karlsson P, Wahlstrom J, Martinsson

T, Nordling M. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved

haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 2001;

9:787–793.

Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z, Martinsson T, Wahlström J,

Karlsson P, Nordling M. A high frequency of germline BRCA1/2 mutations in western Sweden

detected with complementary screening techniques. Fam Cancer 2005; 4:89–96.

Bergman PJ, Camps-Palau MA, Mcknight JA, Leibman NF, Craft DM, Leunga C, Liao J,

Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Wolchok JD. Development of a

xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center.

Vaccine 2006; 24: 4582–4585.

Bergthorsson JT, Jonasdottir A, Johannesdottir G, Arason A, Egilsson V, Gayther S, Borg A,

Hakanson S, Ingvarsson S, Barkardottir RB. Identification of a novel splice-site mutation of the

BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast

cancer patients. Hum Mutat 1998; 1:195–197.

Bianchini A, Musci G, Calabrese L. Inhibition of endothelial nitric-oxide synthase by

ceruloplasmin. J Biol Chem 1999; 274: 20265–20270.

Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy.

Am. J. Ther.2011; DOI: 10.1097/MJT.0b013e3182068cdb (Epub ahead of print).

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

iii

Bingle CD, Fleming RE, Gitlin JD. Interaction of CCAAT/enhancer binding protein and with

the rat caeruloplasmin gene promoter. Biochem J 1993; 294: 473–479.

Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K,

Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG. Biological markers as a

predictor for response and prognosis of unresectable gastric cancer patients treated with 5-

fluorouracil and cis-platinum. Clin Cancer Res 1998; 4: 1469–1474

Bookman MA. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in

patients with recurrent or refractory ovarian or primary peritoneal carcinoma with

overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol

2003; 21:283–90.

Boom R, Sol CJA, Salimaus MMM, Jansen CL. Rapid and simple method for purification of

nucleic acids. J Clin Microbiol 1990; 28:495-503.

Bosco EF. Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis

Rev 1998; 17:25–37.

Boshart M, Zur Hausen HZ. Human papillomavirus (HPV) in Buschke-Lwenstein tumors:

physical state of the DNA and identification of a tandem duplication in the non-coding region of

a HPV 6-subtype. J Virol 1986; 58: 963-966.

Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome

in melanoma. Curr. Opin. Oncol 2011; 23:170–176.

Boyd J, Sonoda Y, Bogomolniy FMG, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat

RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ. Clinicopathologic features of

BRCA linked and sporadic ovarian cancer. JAMA 2000; 283:2260–2265.

Brickner WM. A Study of Five Consecutive Cases Successfully Treated By Operation. Annals

of Surgery 1925; 81, 343-361.

Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge

diagnosis of endometriosis. Am J Obstet Gynecol 1997; 176:572-79.

Brown JR. Human actinomycosis: A study of 181 subjects. Hum Pathol 1973; 4: 319-330.

Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants – a

brief overview. Immunol Lett 2010; 128: 29–35.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

iv

Bryne JC, Tsao MS, Fraser RS, Howley. Human papillomavirus-II DNA in a patient with

chronic laryngotracheobronchial papillomatosis and metastatic squamous cell carcinoma of the

lung. N En eI J Med 1987; 317: 873-878.

Buser K, Joncourt F, Altermatt HJ, Bacchi M, Oberli A, Cerny T. Breast cancer: pretreatment

drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their

correlation with clinical and prognostic characteristics. Annals of Oncology 1997; 8: 335–341.

Bychkov V. Ovarian pathology in chronic pelvic inflammatory disease. Gynecol Obstet Invest

1990; 30:31-33.

Capdevila J, Tsukui T, Rodriquez Esteban C, Zappavigna V, Izpisua Belmonte JC. Control of

vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by

Gremlin. Mol Cell 1999; 4:839-849.

Cappelli-Bigazzi M, Ambrosio G, Musci G, Battaglia C, Bonaccorsi di Patti MC, Golino P,

Ragni M, Chiariello M, Calabrese L. Ceruloplasmin impairs endothelium-dependent relaxation

of rabbit aorta. Am J Physiol 1997; 273: H2843– H2849.

Cappelli-Bigazzi M, Battaglia C, Pannain S, Chiariello M, Ambrosio G. Role of oxidative

metabolism on endothelium-dependent vascular relaxation of isolated vessels. J Mol Cell Cardiol

1997; 29: 871–879.

Carrillo M, Valdez B, Veleva L, Perez T, Vargas L, Schorr M. Microbiologically induced

corrosion of copper intrauterine device by Enterobacter sp. in a synthetic intrauterine medium.

Anti-Corros Methods Mater 2004; 51:331–338.

Casagrande JT, Louie EW, Pike MC, ‘‘Incessant ovulation’’ and ovarian cancer. Lancet 1979;

2:170–3.

Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev

Immunol 2008; 8: 970–976.

Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Burk RD,

Rodriguez AC, Alfaro M, Hutchinson ML, Morales J. An association of cervical inflammation

with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus

(HPV). Cancer Epidemiol Biomarkers Prev 2001; 10:1021–7.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

v

Cecco S, Muraro E, Giacomin E, Martorelli, D, Lazzarini, R, Baldo, P, Dolcetti, R. Cancer

vaccines in Phase II/III clinical trials: state of the art and future perspectives. Curr Cancer Drug

Targets 2010; 11: 85–102.

Chassot F, Negri M, Svidzinski AE. Can intrauterine contraceptive devices be a Candida

albicans reservoir? Contraception 2008; 77:357–360.

Chen B, Athanasiou M, Gu Q, Blair DG. Drm/Gremlin transcriptionally activates p21Cip1 via a

novel mechanism and inhibits neoplastic transformation. Biochem Biophys Res Commun 2002;

295:1135-1141.

Chen B, Blair DG, Plisov S, Vasiliev G, Perantoni AO, Chen Q, Athanasiou M, Wu JY,

Oppenheim JJ, Yang D. Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin

and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J Immunol

2004; 173:5914-5917.

Chen JX, Zheng Y, West M, Tang M. Carcinogens preferentially bind at methylated CpG in the

p53 mutational hot spots. Cancer Res 1998;58: 2070–2075.

Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA. Risk factor for epithelial ovarian

cancer in Beijing, China. Int J Epidemiol 1992; 21:23–9.

Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations

using support vector machines. Proteins 1996; 62:1125-1132.

Clinical and Laboratory Standards Institute Quality Manual; Third Edition. CLSI, 940 West

Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2010

Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of

autoimmunity in a longterm survivor with metastatic colon carcinoma treated with a new

chemoimmunotherapy regimen. J Chemotherapy 2008; 20: 278–281.

Costa FF, Blanc KL, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer.

Stem Cell 2007; 25: 707 – 711.

Costerton JW. Introduction to biofilm. Int J Antimicrob Agents 1999; 11:217–221.

Costerton WJ, Wilson M. Introducing biofilms. Biofilms 2004; 1:1–4.

Cottreau CM, Ness RB, Kriska AM. Physical activity and reduced risk of ovarian cancer. Obstet

Gynecol 2000; 96: 609-14.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

vi

Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper

suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.

Laryngoscope 2001; 111: 696–701.

Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase

gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod

2002; 17:221–227.

Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding

pathogenesis. J Natl Cancer Inst 1983; 71:717–21.

Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in

sera from patients with breast cancer. Int J Cancer 1982; 30:403–408.

Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen

expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration

and matrix metalloproteinase 2 expression. Cancer Res 2005; 65: 2207 – 2215.

Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR. Glutathione S-

transferase pi amplification is associated with cisplatin resistance in head and neck squamous

cell carcinoma cell lines and primary tumors. Cancer Res 2003; 63: 8097–8102

Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, Sheets SM, Wu X, Casiano

CA. Antinuclear autoantibodies in PCa: immunity to LEDGF/p75, a survival protein highly

expressed in prostate tumors and cleaved during apoptosis. Prostate 2005; 62:14–26.

de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of

general primers GP5 and GP6 elongated at their 3’ ends with adjacent highly conserved

sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76:1057-1062.

Dechant M, Beyer T, Merck ST. Effector mechanisms of recombinant IgA antibodies against

epidermal growth factor receptor. J Immunol 2007; 179: 2936–2943.

Denissenko MF, Chen JX, Tang MS, Pfeifer GP. Cytosine methylation determines hot spots of

DNA damage in the human P53 gene. Proc Natl Acad Sci U S A 1997;94:3893–3898.

Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts

at lung cancer mutational hotspots in P53. Science 1996;274:430–432.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

vii

Deziel DE, Comeau Y, Villemur R. Initiation of biofilm formation by Pseudomonas aeruginosa

57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants

deficient in swimming, swarming, and twitching motilities. J Bacteriol 2001; 183:1195-1204.

Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector

T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003;

198:1753-1757.

Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent

oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237:178–182.

Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Jellum E, Koskela P,

GislefossRE, Hallmans G, Paavonen J, Sapp M, Schiller JT, Hakulinen T, Thoresen S, Hakama

M. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for

invasive cervical cancer. J Natl Cancer Inst 1997; 89: 1293–1299.

Dionne MS, Skarnes WC, Harland RM. Mutation and analysis of Dan, the founding member of

the Dan family of transforming growth factor β antagonists. Mol Cell Biol 2001; 21:636-643.

Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu

proteinspecific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol

1997; 15:3363–3367.

Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. Gain of

function mutations in p53. Nat Genet 1993; 4: 42–46.

Donehower LA, Harvey M, Slagle BL, Mcarthur MJ, Montgomery CA, Allanbradley JSB. Mice

deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature

1992; 356: 215–22.

Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant

microorganisms. Clin Microbiol Rev 2002; 15:167–193.

Donlan RM. Biofilm formation. A clinically relevant microbiological process. Health Epidemiol

2001; 33:1387–1392.

Dorgan JF, Hunsberger SA, McMahon RP, Kwiterovich PO, Lauer RM, Horn LV, Lasser NL,

Stevens VJ, Friedman LA, Yanovski JA, Greenhut SF, Chandler DW, Franklin FA, Barton BA,

Buckman DW, Snetselaar LG, Patterson BH, Taylor PRSA. Diet and sex hormones in girls:

findings from a randomized controlled clinical trial. JNCI 2003; 95:132– 41.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

viii

Dosemeci M, Hayes RB, Vetter R, Hoover RN, Tucker M, Engin K, Unsal M, Blair A.

Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey.

Cancer Causes Control 1993; 4: 313–21.

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and

immunoediting. Immunity 2004; 21:137-148.

Durst M, Croce CM, Gissmann L .The physical state of human papillomavirus type 16 in benign

and malignant genital tumors. J. Gen. Virol 1985; 66: 1515-1522.

Dwyer A. Surface-treated catheters - a review. Semin Dialysis 2008; 21:542–546.

El-Deiry WS, Kern SE, Pietenpol JE, Kinzler KW, Vogelstein B. Definition of a consensus

binding site for p53. Nature Genetics 1992; 1: 45–49.

El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE,

Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;

75: 817–825.

El-Manzalawy Y, Dobbs D, Honavar V. Predicted linear B-cell epitopes using string Kernels.

Journal of Molecule Recognition 2008; 21:243-255.

Elmasry K, Gayther SA. Epidemiology of ovarian cancer. In: Reznek, R. (Ed.), Cancer of the

Ovary. Cambridge University Press UK 2007; 115–126.

Elsayed S, George A, Zhang K. Intrauterine contraceptive device associated pelvic

actinomycosis caused by Actinomycetes urogenitalis. Anaerobe 2006; 12:67–70.

Endo K, Meahara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K, et al. Expression of

multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int

J Cancer 1996; 68: 372–7.

Fan T, Lu H, Hu H, Shi L, McClarty GA, Nance DM, Greenberg AH, Zhong G. Inhibition of

apoptosis in Chlamydia-infected cells: blockade of mitochondrial cytochrome c release and

caspase activation. J Exp Med 1998; 187:487–96.

Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens:

immune regulation. Semin Immunol 2010; 22: 125–131.

Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C. Functional interaction between p53, the

TATA binding protein (TBP), and TBP-associated factors in vivo. Molecular and Cellular

Biology 1996; 16: 4295–4304.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

ix

Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet 1971; 2:163

Ferrandina G, Scambia G, Damia G, Tagliabue G, Fagotti A, Benedetti Panici P, Mangioni C,

Mancuso S, D’Incalci M. Glutathione Stransferase activity in epithelial ovarian cancer:

association with response to chemotherapy and disease outcome. Ann Oncol 1997; 8: 343–350

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:

669-676.

Finn OO, Banchereau J. Cancer vaccines: the state of the art. Semin. Immunol 2010; 22:103–

104.

Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular activation switch in the

transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99:15937–15940.

Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V. Changes of biological

features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat

1997; 44: 185–192

Fu SL, Pierre J, Norowitz TAS, Hagler M, Bowne W, Pincus MR, Muelle CM, Zenilman ME,

Bluth ME. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody

dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008;

153: 401–409.

Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D,

Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the

functional maturation of dendritic cells. Nat Med 1996; 2:1096-1103.

Galehouse D, Jenson E, Delucia A. Differences in the integration pattern and episomal forms of

human paillomavirus type 18 DNA found within an invasive cervical neoplasm and its

metastasis. Virology 1992; 186: 339-341.

Galimberti S, Testi R, Guerrini F, Fazzi R, Petrini M. The clinical relevance of the expression of

several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J

Chemother 2003; 15: 374–379

Garbe AI, Vermeer B, Gamrekelashvili J, Wasielewski R, Greten FR, Westendorf AM, Buer J,

Schmid RM, Manns MP, Korangy F, Greten TF. Genetically induced pancreatic

adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune

responses. Cancer Res 2006; 66:508-516.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

x

Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN,

Nice EC, Burgess AW, Ward CW. The crystal structure of a truncated ErbB2 ectodomain reveals

an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11:495–

505.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA,

Benson AB. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin

(FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern

cooperative oncology group study E3200. J Clin Oncol 2007; 25: 1539–1544.

Giri DK, Seyed, Li LY, Lee DF, Ling P, Bartholomeusz G, Wang SC, Hung MC. Endosomal

transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol

2005; 25:11005–18.

Gissmann L, Wolnik L, Ikenberg H. Human papillomavirus types 6 and 11 DNA sequences in

genital and laryngeal papillomas and in some cervical cancers. Proc. Nat/ Acad. Sci. USA 1983;

80: 560-563.

Gnagy S, Eileen E, Ming, Susan S, Devesa, Hartge P, Whittemore AS. Declining ovarian cancer

rates in U.S. women in relation to parity and oral contraceptive use. Epidemiol 2000; 11:102–5.

Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P,

Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D,

Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of

melanoma with interferon. N Engl J Med 2006; 354, 709–718.

Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor

gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878.

Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against

carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in

the absence of autoimmunity. Cancer Res 2002; 62: 6944–6951.

Gupta J, Pilotti S, Rilke F, Shah K. Association of human papillomavirus type 16 with neoplastic

lesions of the vulva and other genital sites by in situ hybridization. Am J Pathol 1987;127: 206–

215.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xi

Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu

proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc

Natl Acad Sci U SA 1989; 89:10578–82.

Hamid D, Baldauf JJ, Cuenin C, Ritter J. Treatment strategy for pelvic actinomycosis: Case

report and review of the literature. Eur J Obstet Gynecol Reprod Biol 2000; 89:197-200.

Hanaoka E, Ozaki T, Nakamura Y, Moriya H, Nakagawara A, Sakiyama S. Overexpression of

Dan causes a growth suppression in p53-deficient SAOS-2 cells. Biochem Biophys Res

Commun 2000; 278:20-26.

Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006;

20: 339–362.

Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women’s health.

Epidemiol Rev 1995; 17:265–86.

Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the

erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 1993; 68: 1140–1145.

Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A. Gynecologic

Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in

advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 1998;

105: 3814 –25.

Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY,

SideriM, Pecorelli S. Carcinoma of the ovary. J Epidemiol Biostat 2001; 6:107–138

Hellstrom I, Goodman G, Pullman J, Yang Y, Hellström KE. Overexpression of HER-2 in

ovarian carcinomas. Cancer Res 2001; 61:2420–3.

Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of

phosphoinositide 3-kinase. Biochem J 1998; 333:757–63.

Henderson SR. Pelvic actinomycosis associated with an intrauterine device. Obstet Gynecol

1973; 41:726–732.

Hendrix RM, Wagenaar M, Slobbe RL, Bruggeman CA. Widespread presence of

cytomegalovirus DNA in tissues of healthy trauma victims. J Clin Pathol 1997; 50:59-63.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xii

Hermeking H, Lengauer C, Polyak K, Tong-Chuan He, Zhang L, Thiagalingam S, Kinzler KW,

Vogelstein B. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Molecular Cell 1997; 1:

3–11.

Herrinton LJ, Stanford JL, Schwarz SM, Weiss NS. Ovarian cancer incidence among Asian

migrants to the United States and their descendants. J Natl Cancer Inst 1994; 86:1336–39.

Hishida A, Hamajima N, Iwata H, Matsuo K, Hirose K, Emi N, Tajima K. Re: population-based,

case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst

2002; 94:1807–1808.

Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell

Death and Differentiation 2003; 10: 404–408.

Hoffman MS, Roberts WS, Solomon P, Gunasekarin S, Cavanagh D. Advanced actinomycotic

pelvic inflammatory disease simulating gynecologic malignancy; A report of two cases. J Reprod

Med 1991; 36:543-545.

Hsu SC, Hung MC. Characterization of a novel tripartite nuclear localization sequence in the

EGFR family. J Biol Chem 2007; 282:10432–40.

Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 2007;

357: 39–51.

Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by

monoclonal antibodies to ErbB- 2 differentially correlate with cellular uptake. Proc Natl Acad

Sci USA 1995; 92: 3353–3357.

Idahl A, Lundin E, Elgh F, Jurstrand M, Moller JK, Marklund I, Lindgren P, Ottander U.

Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papillomavirus,

and polyomavirus are not detectable in human tissue with epithelial ovarian cancer, borderline

tumor, or benign conditions. Am J Obstet Gynecol 2010; 202: 71.e1-e6.

Idahl A, Lundin E, Jurstrand M, Kumlin U, Elgh F, Ohlson N, Ottander U. Chlamydia

trachomatis and Mycoplasma genitalium Plasma Antibodies in Relation to Epithelial Ovarian

Tumors. Infect Dis Obstet Gynecol 2011; DOI:10.1155/2011/824627.

Ikeda N, Miyoshi Y, Yoneda K. Frequency of BRCA1 and BRCA2 germline mutations in

japanese breast cancer families. Int J Cancer 2001; 91:83–88.

Isaacs NW: Cystine knots. Curr Opin Struct Biol 1995; 5:391-395.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xiii

Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ.

Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int. J.

Cancer 1996; 65: 230–237.

Izquierdo MA, van der Zee AGJ, Vermorken JB, van der Valk P, Belien JAM, Giaccone G,

Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE, Scheper RJ.

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis

in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230–1237.

James GA, Swogger E, Wolcott R, Pulcini ED, Secor P, Sestrich J. Biofilms in chronic wounds.

Wound Repair Regen 2008; 16:37–44.

Jefferson KK. What drives bacteria to produce a biofilm? FEMS Microbiol Lett 2004; 236:163–

73.

Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet M L,

Rodríguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H. Allergo Oncology: the role of

IgE mediated allergy in cancer. Allergy 2008; 63: 1255–1266.

Jonas L, Baguhl F, Wilken HP, Jass HJ, Nizze H. Copper accumulation in Actinomyces druses

during endometritis after long-term use of an intrauterine contraceptive device. Ultrastruct Pathol

2002; 26:323-329.

Juhl H. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-

2/neu by ribozyme targeting. J Biol Chem 1997; 272:29482–6.

Jungbluth AA, Silva WA, Iversen K, Frosina D, Zaidi B, Coplan K. Expression of cancer-testis

(CT) antigens in placenta. Cancer Immun. 2007; 7: 15 – 29.

Kalejs M, Erenpreis J. Cancer/testis antigens and gametogenesis: a review and "brain-storming"

session. Cancer Cell Int 2005; 5: 4 – 15.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC,

Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for

castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–422.

Karagiannis P, Singer J, Hunt J, Gan SKE, Rudman SM, Mechtcheriakova D, Knittelfelder R,

Daniels TR, Hobson PS, Beavil AJ. Characterisation of an engineered trastuzumab IgE antibody

and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol

Immunother 2009; 58: 915–930.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xiv

Karbassi BM, Artaud C, Jousheghany F. Reduction of spontaneous metastases through induction

of carbohydrate cross-reactive apoptotic antibodies. J. Immunol. 2005; 174: 7057–7065.

Kavallaris M, Leary JA, Barrett JA, Friedlander ML. MDR1 and multidrug resistance-associated

protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 1996; 102: 7–16.

Keene JD. Why is Hu where? Shuttling of early response gene messenger RNA subsets. Proc

Natl Acad Sci USA 1999; 96:5–7.

Keith WN, Stallard S, Brown R. Expression of mdr1 and gst-pi in human breast tumours:

comparison to in vitro chemosensitivity. British Journal of Cancer 1990; 61: 712–716.

Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A. Distribution of HER2 (V655)

genotypes in breast cancer cases and controls in the United States. Cancer Lett 2001;173: 37–41.

Khokha MK, Hsu DR, Brunet LJ, Dionne MS, Harland RM. Gremlin is the BMP antagonist

required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet 2003;

34:303-307.

Khoo US, Chan KY, Cheung AN , Xue1 WC, Shen DH, Fung KY, Hextan YS, Ngan KW, Choy

CP, Pang CSP, Poon AYA, Ozcelik H. Recurrent BRCA1 and BRCA2 germline mutations in

ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat

2002; 486.

Kilbane M, Shering S, Symith D, Mcdermott E, O’higgins N, Symith P. Thyroid peroxidase

(TPO): an autoantigen common to the thyroid and breast. J. Endocrinol. 1998; 156: 323.

Kiviat NB, Paavonen JA, Brockway J, Critchlow CW, Brunham RC, Stevens CE, Stamm WE,

Kuo CC, DeRouen T, Holmes KK. Cytologic manifestations of cervical and vaginal infections:

1, epithelial and inflammatory cellular changes. JAMA 1985; 253: 989 –96.

Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined

specificity. Nature 1975; 256: 495–497.

Kohler MF, Marks JR, Wiseman RW. Spectrum of mutation and frequency of allelic deletion of

the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513– 9.

Kondi-Pafiti A, Smyrniotis V, Frangou M, Papayanopoulou A, Englezou M, Deligeorgi H.

Immunohistochemical study of ceruloplasmin, lactoferrin and secretory component expression in

neoplastic and non-neoplastic thyroid gland diseases. Acta Oncol 2000; 39: 753–756.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xv

Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF.

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in

hepatocellular carcinoma. Clin Cancer Res 2004; 10:4332-4341.

Koshiyama M, Yoshida M, Fujii H. Ovarian actinomycosis complicated by diabetes mellitus

simulating an advanced ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 1999; 87:95–99.

Koskela P, Anttila T, Bjorge T. Chlamydia trachomatis infection as a risk factor for invasive

cervical cancer Int J Can 2000; 85:35–39.

Koumenis C, Alarcon R, Hammond E. Regulation of p53 by hypoxia: dissociation of

transcriptional repression and apoptosis from p53-dependent transactivation. Molecular and

Cellular Biology 2001; 21: 1297–1310.

Kuhn DE, Beall CJ and Kolattukudy PE. The cytomegalovirus US28 protein binds multiple CC

chemokines with high affinity. Biochem Biophys Res Commun, 1995; 211:325–330.

Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune

evasion in cancer. Cancer Immunol Immunother 2006; 55:237-245.

Laemmli Uk. Cleavage of structural proteins during the assembly of the head of bacteriophage

T4. Nature 1970; 227: 680-685.

Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990; 4: 1–8.

Lane DP, Crawford LV . T antigen is bound to a host protein in SV40 transformed cells,” Nature

1979; 278: 261–263.

Lappin DW, Hensey C, McMahon R, Godson C, Brady HR. Gremlins, glomeruli and diabetic

nephropathy. Curr Opin Nephrol Hypertens 2000; 9:469-472.

Lax I, Burgess WH, Bellot F, Ullrich A, Schlessinger J, Givol D. Localization of a major

receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol 1988;

8:1831–4.

Lechevalier HA. The actinomycetes III. A practical guide to generic identification of

actinomycetes. In: Williams ST et al. (eds) Bergey’s Manual Systematic Bacteriology. Volume

4. Williams & Wilkins, 1989; pp. 2344–2347.

Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY. Altered microRNA expression in

cervical carcinomas. Clin Cancer Res 2008; 14: 2535–2542.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xvi

Lee NC, Rubin GL, Ory HW, Burkman RT. Type of intrauterine device and the risk of pelvic

inflammatory diseases. Obstet Gynecol 1983; 62:1-6.

Lee PL, Gelbart T, West C, Halloran C, Felitti V, Beutler E. A study of genes that may modulate

the expression of hereditary hemochromatosis: transferring receptor-1, ferroportin,

ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and

hepcidin. Blood Cells Mol Dis 2001; 27: 783–802.

Lewis R. A review of bacteriological culture of removed intrauterine contraceptive devices. BR

J fam Plan 1988; 24: 95-97.

Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear

localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol.

2001; 3:802–808.

Linzer DIH, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in

SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43–52.

Liu X, Miller CW, Koeffler PK, and Berk AJ. The p53 activation domain binds the TATA box-

binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription.

Molecular and Cellular Biology 1993; 13: 3291–3300.

Liu Y, Wanga L, Zhoub X, Huc S, Zhanga S, Wub H. Effect of the antimicrobial decapeptide

KSL on the growth of oral pathogens and Streptococcus mutans biofilm. Int J Antimicro Agents

2011; 37:33–38.

Lu H, Levine AJ. Human TAF (II) 31 protein is a transcriptional coactivator of the p53 protein.

Proceedings of the National Academy of Sciences of the United States of America 1995; 92:

5154–5158.

Lu M, Nakamura RM, Dent ED, Zhang JY, Nielsen FC, Christiansen J, Chan EK, Tan EM.

Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J

Pathol 2001; 159: 945–953.

Lute KD, May KF, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA,

Zheng P, Liu Y. Human CTLA4 knock-in mice unravel the quantitative link between tumor

immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 2005; 106: 3127–3133.

Luza SC, Speisky HC. Liver copper storage and transport during development: implications for

cytotoxicity. Am J Clin Nutr 1996; 63: 812S–820S.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xvii

MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein

microarrays. Nature 2006; 439:168–74.

Mah TF, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends

Microbiol 2001; 9:34–39.

Mahony JB, Luinstra KE, Jang D, Sellors J, Chernesky MA. Chlamydia trachomatis

confirmatory testing of PCR-Positive genitourinary specimens using a second set of plasmid

primer. Mol Cell Probes 1992; 6:381–388.

Manfredi R, Alampi G, Talo S, Calza L, Tadolini M, Martinelli GN, Chiodo F. Silent oophoritis

due to cytomegalovirus in a patient with advanced HIV disease. Int J STD AIDS 2006; 11: 410-

412.

Manias D, Ostrow R, Mcglennen R, Estensen R, Faras A. Characterization of integrated human

papillomavirus type 11 DNA in primary and metastatic tumors from a renal transplant recipient.

Cancer Research 1989; 49: 2514-2519.

Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL,

Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian

cancer. Cancer Res 1991; 51: 2979-2984.

Marrie TJ, Costerton JW. A scanning and transmission electron microscopic study of the

surfaces of intrauterine contraceptive devices. Am J Obstet Gynecol 1983; 146:384–394.

Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC.

Trastuzumab beyond progression: a cost-utility analysis. Ann Oncol 2010; 21: 2161–2168.

Mcbride WH, Chiang CS, Olson JL. Failla memorial lecture – a sense of danger from radiation.

Radiat. Res. 2004; 162: 1–19.

McPherson CP, Sellers TA, Potter JD, Bostick RM and Folsom AR. The Iowa Women’s Health

Study. Am J Epidemiol 1996; 143:1195– 1202.

Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A. Cancer-testis antigens in haematological

malignancies. Br J Haematol 2007; 136: 769 – 776.

Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB

receptors self-associate in cell membranes. J Biol Chem 2002; 277:4704–12.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xviii

Michos O, Panman L, Vintersten K, Beier K, Zeller R, Zuniga A. Gremlin-mediated BMP

antagonism induces the epithelialmesenchymal feedback signaling controlling metanephric

kidney and limb organogenesis. Development 2004; 131:3401-3410.

Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY. HER2 codon 655

polymorphism and risk of breast cancer in African American and whites. Breast Cancer Res

Treat 2003; 79:355–364.

Milner BJ, Allan LA, Eccles DM. p53 mutation is a common genetic event in ovarian carcinoma.

Cancer Res 1993; 53: 2128– 32.

Milner J. Flexibility: the key to p53 function? Trends Biochem 1995; 20: 49–51.

Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to

cancer. Curr Drug Targets 2004; 5:389—406.

Mitao M, Reumann W, Winkler B, Richart RM, Fujiwara A, Crum CP. Chlamydial cervicitis

and cervical intraepithelial neoplasia: an immunohistochemical analysis. Gynecol Oncol 1984;

19: 90–97.

Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human

bax gene. Cell 1995; 80: 293–299.

Mori M, Nishida T, Sugiyama T, Komai K, Yakushiji M, Fukuda K, Tanaka T, Yokoyama M,

Sugimori H. Anthropometric and other risk factors for ovarian cancer in a case–control study.

Jpn J Cancer Res 1998; 89:246–53.

Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin

Pract Oncol 2005; 2:90-97.

Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional

activation of ceruloplasmin by iron deficiency. J Biol Chem 2000; 275: 21048–21054.

Mullenbach R, Lagoda PJ, Welter C. An efficient salt– chloroform extraction of DNA from

blood and tissues. Trends Genet 1989; 5, 391.

Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, Jansen PL.

Overexpression of the gene encoding the multidrug resistance-associated protein results in

increased ATP-dependent glutathione S-conjugate transport. PNAS 1994; 91: 13033–13037.

Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity

against cancer. Clin Cancer Res. 2003; 9:4296-4303.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xix

National Cancer Institute: www.cancer.gov/clinicaltrials

National Cancer Registry Program. Three year report of population based cancer registries

[2006-2008], Bangalore, India; 2010.

Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch

HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case

control studies. Am J Epidemiol 2002;155:217–224

Ness RB, Griss JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ.

Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiol

2000; 11:111–117.

Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A. Haplotype and

phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international

study. Am J Hum Genet 1996; 58:271–80.

Nooter K, de la Reviere GB, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ.

The prognostic significance of expression of the multidrug resistance-associated protein (MRP)

in primary breast cancer. Br J Cancer 1997; 76: 486–93.

Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, van Wingerdern KE, Burger H,

Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT,

Stoter G. Expression of the multidrug resistance associated protein (MRP) gene in human

cancers. Clin. Cancer Res 1995; 1: 1301–1010.

O’Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas

aeruginosa biofilm development. Mol Microbiol 1998a; 30:295-304.

O’Toole GA, Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365

proceeds via multiple, convergent signaling pathways: A genetic analysis. Mol Microbiol 1998b;

28:449-461.

Okuda T, Otsuka J, Sekizawa A, Saito H, Makino R, Kushima M, Farina A, Kuwano Y, Okai T.

p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear

cell cancer. Gynecol Oncol 2003; 88: 318– 25.

Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998; 187:1163–1167.

Old LJ. Cancer/testis (CT) antigens—a new link between gametogenesis and cancer. Cancer

Immun 2001; 1: 1 – 9.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xx

Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased

populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.

Cancer Res 2005; 65:2457-2464.

Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H. Expression of the multidrug resistance

associated-protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 1995; 72: 550–4.

Otten MA, Rudolph E, Dechant M. Immature neutrophils mediate tumor cell killing via IgA but

not IgG Fc receptors. J Immunol 2005; 174: 5472–5480.

Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E,

Chevillard S. Expression of genes involved in chemoresistance, proliferation and apoptosis in

clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res

2002; 22: 121–128

Pakunlu RI, Cook TJ, Minko T. Simultaneous modulation of multidrug resistance and

antiapoptotic cellular defence by MDR1 and BCL2 targeted antisense oligonucleotides enhances

the anticancer efficacy of doxorubicin. Pharm Res 2003;20:351—9.

Pal Z, Urban E, Dosa E, Pal A, Nagy E. Biofilm formation on intrauterine devices in relation to

duration of use. Med Microbiol 2005; 54:1199-1203.

Papewalis J, Nikitin AY, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the

human erbB-2/HER2 gene. Nucleic Acids Res 1991; 19:5452.

Parazzini F, Franceschi S, Vecchia CL, Fasoli M. Review: the epidemiology of ovarian cancer.

Gynecol Oncol 1990; 43: 9–23.

Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L. Pelvic inflammatory

disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 1996; 5:667–669.

Parazzini F, Negri E, La Vecchia C L, Benzi G, Chiaffarino F, Polatti A, Francheschi S. Role of

reproductive factors on the risk of endometrial cancer. Int J Cancer 1998; 76:784–86.

Pardoll DM. Inducing autoimmune disease to treat cancer. Proc. Natl Acad. Sci. USA 1999; 96:

5340–5342.

Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of

HER2. Clin Breast Cancer 2008; 8:392–401.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxi

Parmigiani RB, Bettoni F, Vibranovski MD, Lopes MH, Martins WK, Cunha IW.

Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral

response in cancer patients. Proc Natl Acad Sci U S A 2006; 103: 18066 – 18071.

Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in

the CNS and prevents free radical injury. J Neurosci 2002; 22: 6578–6586.

Pearce JJ, Penny G, Rossant J. A mouse cerberus/Dan-related gene family. Dev Biol 1999;

209:98-110.

Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after

tubal sterilization: findings from the US Collaborative Preview of Sterilization. Am J Obstet

Gynecol 1996; 174:1161–1170.

Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Khabbaz HA, Brown AC, Presta LG, Meng

YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a

humanized FcRn mouse model: potential application in humorally mediated autoimmune

disease. Int Immunol 2006; 18: 1759–1769.

Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker

MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and

promotes hormone independent growth in human breast cancer cells. Oncogene 1995; 10:2435–

46.

Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-

2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

Oncogene. 1994; 9:1829–38.

Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Hefler L, Horvat R,

Reinthaller A, Zeillinger R, Krainer M. In ovarian cancer the prognostic influence of HER2/neu

is not dependent on the CXCR4/SDF-1 signalling pathway. Br J Cancer. 2007; 96: 485–91.

Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H, Lopes C, Medeiros R. HER2

polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 2004; 13:177–181.

Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B

vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer

Lett. 2009; 86: 2–21.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxii

Posadas EM, Davidson B, Kohn EC. Proteomics and ovarian cancer: implications for diagnosis

and treatment: a critical review of the recent literature. Curr Opin Oncol 2004; 16:478-484.

Prozialeck WC, Fay MJ, Lamar PC, Pearson CA, Sigar I, Ramsey KH. Chlamydia trachomatis

disrupts N-cadherin-dependent cell-cell junctions and sequesters beta-catenin in human cervical

epithelial cells. Infect Immun 2002; 70:2605–2613.

Pruthi V, Al-Janabi A, Pereira. Characterization of biofilm formed on intrauterine devices.

Indian J Med Microbiol 2003; 21:161-165.

Pruthi V, Al-Janabi A, Pereira. Characterization of biofilm formed on intrauterine devices.

Indian J Med Microbiol 2003; 21:161-165.

Putman HC, Dockerty MB, Waugh JM. Abdominal actinomycosis: an analysis of 122 cases.

Surgery 1950; 28:781-801.

Q’ Connor KF, Bagg MN, Croley MR, Schabel SI. Pelvic actinomycosis associated with

intrauterine devices. Radiology 1989; 170:559-560.

Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis,

prevention, and management. Lancet Infect Dis 2007; 7:645–657.

Raad I, Hanna HA. Intravascular catheter-related infections. New horizons and recent advances.

Arch Intern Med 2002; 162:871–878.

Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, Salvarsdottir,

Steingrimsson AE, Thorlacius S. BRCA2, but not BRCA1, mutations account for familial

ovarian cancer in Iceland: a population-based study. Eur J Cancer 2004; 40: 2788–2793.

Rando RF, Sedlacek TV, Hunt J, Jensen AB, Kurman RJ, Lancaster WD. Verrucous carcinoma

of the vulva associated with an unusual type 6 human papillomavirus. Obstet Gynecol 1986; 67:

70s-75s.

Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug

Discov Today 2008; 13: 30–37.

Reid G. Biofilms in infectious diseases and on medical devices. Int J Antimicrob Agents 1999;

11:223–226.

Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A,

Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF. Correlation of

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxiii

p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian

cancer. Clin Cancer Res. 2001; 7: 2984–97.

Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O,

Zielinski CC and Jensen-Jarolim E. Generation of peptide mimics of the epitope recognized by

trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004; 173: 394–401.

Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner

O, and Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope

vaccination. Cancer Res 2007; 67: 3406–3411.

Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of

epidemiological evidence. Clin Endocrinol 1998; 49: 695–707.

Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer.

Cancer Epidemiol Biomarkers Prev 1995; 4:447-451.

Risch HA, McLaughlin JR, Cole DE. Prevalence and penetrance of germline BRCA1 and

BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet

2001; 68: 700-710.

Risch HA. Hormonal etiology of epithelial ovarian cancer with a hypothesis concerning the role

of androgen and progesterone. J Natl Cancer Inst 1998; 90:1774–1786.

Romano E, Rossi M, Ratzinger, Silva RBD, Betts BC, Chung DJ, Avogadri F, Fink MJ, Angelo

ET, Mehrara B, Heller G, Münz C, Bonnet GA , Young JW. Peptide-loaded langerhans cells,

despite increased IL15 secretion and T cell activation in vitro, elicit anti-tumor T cell responses

comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 2011;

17: 1984–1997.

Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12:S3–8.

Runnebaum IB, Maier S, Tong XW. Human papillomavirus integration is not associated with

advanced epithelial ovarian cancer in German patients. Cancer Epidemiol Biomarkers Prev 1995;

4: 573-575.

Ryan SO, Turner MS, Gariepy J, Finn OJ. Tumor antigen epitopes interpreted by the immune

system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res 2010;

70: 5788–5796.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxiv

Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and

commentary. Cancer Immun. 2004; 4: 1 – 15.

Schaber JA, Carty NL, McDonald NA, Graham ED, Cheluvappa R, Griswold JA, Hamood AN.

Analysis of quorum sensing-deficient clinical Isolates of Pseudomonas aeruginosa. J Med

Microbial 2004; 53:841-853.

Schierholz JM, Beuth J. Implant infections: a haven for opportunistic bacteria. J Hosp Infect

2001; 49:87–93.

Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus

vaccination. Cancer Res 2006; 66:10229–10232.

Schulze WX, Mann DL, Jones RB, Gordus A, Krall JA. Phosphotyrosine interactome of the

ErbB-receptor kinase family. Mol Syst Biol 2005; 1: 2005- 2008.

Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe

infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology

practices: assessment of clinical consequences. Support Care Cancer 2008; 16: 393–398.

Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995; 23: 208–218

Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I,

Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S,

Tanaka K. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian

cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese

population. Clin Cancer Res 2001; 7: 3144–3150.

Shah KV, Howley PM. Papillomaviruses. In: Fields BN, Knipe DM, Howley PM, (eds) Fields

Virology 1996; Vol. 2, pp 2077–2109. Philadelphia: Lippincott-Raven

Shahin MS, Hughes JH, Sood A, Buller RE. The prognostic significance of p53 tumor

suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89: 2006– 17.

Sharma TM, Nadasdy T, Leech RW, Kingma DW, Johnson LD, Hanson-Painton O. In situ DNA

hybridization study of 'primary' cytomegalovirus (CMV) oophoritis. Acta Obstet Gynecol Scand

1994; 73:429-43.

Sheever MA, Disis ML, Bernahrd H, Grarlow JR, Hand SL, Huseby ES, Qin HL, Takahashi M,

Chen W. Immunity to oncogenic proteins. Immunol Rev 1995; 145:33–59.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxv

Shevchenko A, Tomas H, Vorm O, Havlis J, Olsen JV, Mann M. In-gel digestion for mass

spectrometric characterization of proteins and proteomes. Nat Protoc 2006; 1: 2856- 2860

Shibata A, Whittemore AS. Genetic predisposition to prostate cancer: possible explanations for

ethnic differences in risk. Prostate 1997; 32:65–72.

Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B,

Fox JA, Presta LG. High resolution mapping of the binding site on human IgG1 for Fcg RI, Fcg

RII, Fc g RIII, and FcRn and design of IgG1 variants with improved binding to the Fcg R. J Biol

Chem 2001; 276: 6591–6604.

Shu X0, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer

in Shanghai. Cancer Res 1989; 49:3670-3674.

Shu XO, Louise A. Brinton, Zheng W, Gao YT, Fan J, Joseph F, Fraumeni JR. A population-

based case–control study of endometrial cancer in Shanghai, China. Int J Cancer 1991; 49:38–43.

Siena S, Jones RG, Adenis A, Thaler J, Preusser P, Aguilar EA, Aapro MS , Loos AH, Esser R,

Wilke H. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during

treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine

premedication. Cancer 2010; 116:1827–1837.

Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian

of the genome. Cancer Res 2000; 60: 6788–6793.

Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, Maucione A, Kenda R,

Zucali R, Veronesi U. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and

benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997; 89: 639–645

Simpson AJG, Caballero OL, Jungbluth A, Chen Y, Old LJ. Cancer/testis antigens,

gametogenesis, and cancer. Nat Rev Cancer 2005; 5: 615 – 625.

Singer B, Essigmann JM. Site-specific mutagenesis: retrospective and prospective.

Carcinogenesis 1991;12:949–955.

Smyth PP, Shering SG, Kilbane MT, Murray MJ, McDermott EWM, Smith DF, O’Higgins NJ.

Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J

Clin Endocrinol Metab 1998; 83: 2711–2716.

Soussi T, Be´roud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat.

Rev. Cancer 2001; 233–240.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxvi

Soussi T, Be´roud C. Significance of TP53 mutations in human cancer: a critical analysis of

mutations at CpG dinucleotides. Hum. Mutat 2003; 23: 192–200.

Soussi T. p53 antibodies in the sera of patients with various types of cancer. A review. Cancer

Res 2000; 60:1777–1788.

Soussi T. The p53 tumour suppressor gene: a model for molecular epidemiology of human

cancer. Mol Med Today 1996; 5: 32–37.

Spinardi L, Mazars R, Theillet C. ProUKols for an improved detection of point mutations by

SSCP. Nucleic Acids Res 1999; 4009.

Steffensen KD, Waldstrom M, Jeppesen U, Jakobsen E, Brandslund I, Jakobsen A. The

prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer.

Int J Gynecol Cancer 2007; 17:798–807.

Stein WD. The movement of molecules across cell membranes. New York: Academic Press;

1967.

Stern DF, Kamps MP, Cao H. Oncogene activation of p185neu stimulates tyrosin

phosphorylation in vivo. Mol Cell Biol 1988; 8:3969–3973.

Stevenson BJ, Iseli C, Panji S, Zahn-Zabel M, Hide W, Old L. Rapid evolution of cancer/testis

genes on the X chromosome. BMC Genomics 2007; 8: 129 – 139.

Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A

survey of humoral immune response of cancer patients to a panel of human tumor antigens. J

Exp Med 1998; 187:1349– 1354.

Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. Association

between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients

with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936–942

Stratton JF, Pharoah PDP, Smith SK, Easton DF, Ponder BAJ. A systematic review and meta-

analysis of family history and risk of ovarian cancer. Br J Obstet Gynecol 1998; 105:493-499.

Suzich JA, Ghim SJ, Hill FJP, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB,

Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the

development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 1995; 92 : 11553–11557.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxvii

Suzuki H, Graziano DF, McKolanis J, Finn OJ. T Cell- Dependent antibody responses against

aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin

Cancer Res 2005; 11:1521-1526.

Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Frenkel

EP, Minna JD, Fujisawa T, Gazdar AF. DNA methylation-associated inactivation of TGF beta

related genes DRM/Gremlin,RUNX3, and HPP1 in human cancers. Br J Cancer 2005; 93:1029-

1037.

Swisher E. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. Curr

Womens Health Rep 2003; 3: 27–32.

Talos F, Moll UM. Role of the p53 family in stabilizing the genome and preventing

polyploidization. Advances in Experimental Medicine and Biology 2010; 676: 73–91.

Tamakoshi K, Konda T, Yatsuya H, Hori Y, Kikkawa F, Toyoshima H. Trends in the mortality

(1950-1997) and incidence (1975-1993) of malignant ovarian neoplasm among Japanese women:

analyses by age, time and birth cohort. Gynecol oncol 2001; 83:64-71.

Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune

system. Immunol Rev 2008; 222:328–40.

Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis.

J Clin Invest 2001; 108:1411–1415.

Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB,

Wolf J. Identification of tissue- and cancer-selective promoters for the introduction of genes into

human ovarian cancer cells. Gynecol Oncol 2002; 85: 451–458.

Tavtigian SV, Simard J, Rommens J, Couch JF, Eidens DS, Neuhausen S, Merajver S,

Thorlacius S, Offit K, Lyonnet DS, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T,

Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell

JT, Morrison M, Nguyen K, Peng K, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow

M, Stroup M, Swedlund B, Swense J, Teng D, Thomas A, Tran T, Tranchant M, Feldhaus JW,

Wong AKC, Shizuya H, Eyfjord JE, Albright LC, Tranchant M, Labrie F, Skolnick MH, Weber

B, Kamb A and Goldgar DE. The complete BRCA2 gene and mutations in chromosome 13q-

linked kindreds. Nat Genet 1996; 12:333–337.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxviii

Telesco SE, Radhakrishnan R. Atomistic insights into regulatory mechanisms of the HER2

tyrosine kinase domain: a molecular dynamics study. Biophys J 2009; 96: 2321–34.

Tenke P, Riedl CR, Jones GL, Williams GJ, Strickler D, Nagy E. Bacterial biofilm formation on

urologic devices and heparin coatings as preventive strategy. Int J Antimicrob Agents 2004;

23S:S67–74.

The future of monoclonal antibodies therapeutics: innovation in antibody engineering, key

growth strategies and forecasts to 2011. Business Insights 2006.

Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in

patients with ovarian cancer. Obstet Gynecol 2003; 101:885–891

Topol LZ, Bardot B, Zhang Q, Resau J, Huillard E, Marx M, Calothy G, Blair DG: Biosynthesis,

post-translation modification, and functional characterization of Drm/Gremlin. J Biol Chem

2000; 275:8785-8793.

Topol LZ, Marx M, Laugier D, Bogdanova NN, Boubnov NV, Clausen PA, Calothy G, Blair

DG. Identification of drm, a novel gene whose expression is suppressed in transformed cells and

which can inhibit growth of normal but not transformed cells in culture. Mol Cell Biol 1997;

17:4801-4810.

Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic

therapy for early-stage breast cancer. Curr Oncol 2008; 15: S16–S29.

Trottier AM, Provencher D, Mes-Masson AM, Vauclair R, and Coutlee F. Absence of Human

Papillomavirus Sequences in Ovarian Pathologies. J Clin Microbiol 1995; 33: 1011–1013

Tzukerman M, Shachaf C, Ravel Y, Braunstein I, Cohen-Barak O, Yalon- Hacohen M, Skorecki

KL. Identification of a novel transcription factor binding element involved in the regulation by

differentiation of the human telomerase (hTERT) promoter. Mol Biol Cell 2000; 11: 4381–4391.

Vega A, Campos B, Paillerets B, Bond PM, Janin N, Douglas FS, Domènech M, Baena M,

Pericay C, Alonso C, Carracedo A, Baiget M, Diez O. The R71G BRCA1 is a founder spanish

mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001; 419: 1–6.

Venkitaraman AR. Cancer susceptibility and the functions of BRCA1and BRCA2. Cell

2002;108:171- 182.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxix

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J,

Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in

vivo. Nature 2007; 445: 661–665.

Vogelstein B, Lane D, and Levine AJ. Surfing the p53 network. Nature 2000; 408: 307–310.

von Eiff C, Jansen B, Kohnene W, Becker K. Infections associated with medical devices.

Pathogenesis, management and prophylaxis. Drugs 2005; 65:179–214.

Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on

hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27:407-414.

Wang LXJ, Westwood JA, Moeller M, Duong1 CPM, Wei-Zen Wei, Malaterre J, Trapani JA,

Neeson P, Smyth MJ, Kershaw MJ, Darcy PK. Tumor ablation by gene-modified T cells in the

absence of autoimmunity. Cancer Res. 2010; 70: 9591–9598.

Wang SC, Lien HC, Xia W, Chen IF, Lo WE, Wang Z, Seyed MA, Lee DF, Bartholomeusz G,

Yang FO, Giri DK , Hung MC. Binding at and transactivation of the COX-2 promoter by nuclear

tyrosine kinase receptor ErbB-2. Cancer Cell 2004; 6:251–61.

Weese WC, Smith IM. A study of 57 cases of actinomycosis over a 36-year period. A diagnostic

‘failure’ with good prognosis after treatment. Arch Intern Med 1975; 135:1562-1568.

Weiss, NS, Homochuk T, Young JC. Incidence of the histologic types of ovarian cancer; the

U.S. Third National Cancer Survey 1969-71. Gyn Oncol 1977; 5, 161.

Wen WH, Reles A, Runnebaum IB, Halley JS, Bernstein L, Jones LA, Felix JC, Kreienberg R,

el-Naggar A, Press MF. p53 mutations and expression in ovarian cancers: correlation with

overall survival. J Int Gynecol Pathol 1999; 18: 29 – 41.

Wernli KJ, Ray RM, Gao DL, De Roos AJ, Checkoway H, Thomas DB. Menstrual and

reproductive factors in relation to risk of endometrial cancer in Chinese women. Cancer Causes

Control 2006; 17: 949–55.

Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 gene mutation in

human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86:1549– 51.

Westoff C. IUDs and colonization or infection with Actinomyces. Contraception 2007; 75:48-50.

Whittemore AS. Personal characteristics relating to risk of invasive epithelial ovarian cancer in

older women in the United States. Cancer 1993;71:558–65

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxx

WHO. Cancer epidemiology databases. France: international agency for research on cancer;

2001 (http://www.iarc.fr)

Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hummerich JI, Muller

DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A. Evidence for a novel tumor

suppressor gene on chromosome15 associated with progression to a metastatic stage in breast

cancer. Oncogene 1996; 12:973-978.

Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE. The

ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A

nuclear chaperone. J Cell Biol 2004; 167:469–78.

Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of

antibodies against p53 in lung cancer patients appears to be dependent on the type of p53

mutation. Cancer Res. 1992; 52:4168–4174.

Wolf AS, Kreiger D. Bacterial colonization of intrauterine devices (IUDs). Arch gynecol 1986;

239:31-37.

Wu QJ, Guo M, Lu ZM, Li T, Qiao1 HZ, Ke Y. Detection of human papillomavirus-16 in

ovarian malignancy. BJC 2003; 89: 672 – 675.

Xu WH, Xiang YB, Ruan ZX, Zheng W, Cheng JR, Dai Q, Gao YT, Shu XO. Menstrual and

reproductive factors and endometrial cancer risk: Results from a population-based case–control

study in urban Shanghai. Int J Can 2004; 108: 613–19.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C,

Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver

carcinomas. Nature 2007; 445: 656–660.

Yen ML, Yen BL, Bai CH, Lin RS. Risk factors for ovarian cancer in Taiwan: a case– control

study in a low-incidence population. Gynecol Oncol 2003;89:318–24.

Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by

tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine

design. J Immunol. 2001; 166: 5271–5278.

Yu J, Solano FX, Seethala RR. Bilateral cytomegalovirus (CMV) oophoritis mimicking widely

metastatic carcinoma: a case report and review of the literature. Diagnostic Pathology 2007;

2:50.

Genetic, molecular and microbiological basis for ovarian carcinoma from a low incidence population

2012

xxxi

Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman

HF, Mulder NH, de Vries EGE, Baas F, Borst P. Analysis of the expression of MRP, the gene for

a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell

lines. Cancer Res 1993; 53: 1747–1750.

Zeegers MPA, Poppel FV, Spruijt VRL, Ostrer H. Founder mutations among the Dutch. Eur J

Hum Genet 2004; 12:591–600.

Zendman AJW, Ruiter DJ, van Muijen GNP. Cancer/testis-assosiated genes: identification,

expression profile, and putative function. J Cell Physiol 2003; 194: 272 – 288.

Zhang JY, Chan EKL, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding

motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999; 189: 1101–1110.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis

A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence,

and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213.

Zhang M, Lee AH, Binns CW. Reproductive and dietary risk factors for epithelial ovarian cancer

in China. Gynecol Oncol 2004; 92: 320– 26.

Zhang M, Yang ZY, Binns CW, Lee AH. Diet and ovarian cancer risk: a case–control study in

China. Br J Cancer 2002; 86:712–17.

Zheng H, Kavanagh JJ, Hu W. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007;

17: 325–338.

Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001;

293:251–253

Ziogas A, Gildea M, Cohen P, Bringman D, Taylor TH, Seminara D, Barker D, Casey G, Robert

H, Shu-Yuan Liao, Thomas D, Noble B, Kurosaki T, Culver HA. Cancer risk estimates for

family members of a population-based family registry for breast and ovarian cancer. Cancer

Epidemiol Biomarkers Prev 2000; 9:103–111.

Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;

6:295-307.

Zuniga A, Haramis AP, McMahon AP, Zeller R: Signal relay by BMP antagonism controls the

SHH/FGF4 feedback loop in vertebrate limb buds. Nature 1999; 401:598-602.